Tower Research Capital (TRC)’s iSpecimen ISPC Stock Holding History

Tower Research Capital (TRC)’s Portfolio ISPC Stock Details ISPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.04K	Sell	166 -1	-0.6%	-$11	﹤0.01%	4732
2025 Q4	$1.73K	Buy	167 +108	+183%	+$2.74K	﹤0.01%	4647
2025 Q3	$3.04K	Sell	59 -96	-62%	-$4.51K	﹤0.01%	4551
2025 Q2	$6.06K	Buy	155 +80	+107%	+$3.72K	﹤0.01%	4130
2025 Q1	$3.16K	Buy	75 +72	+2,400%	+$5.47K	﹤0.01%	4461
2024 Q4	$348	Sell	3 -26	-90%	-$4.34K	﹤0.01%	5309
2024 Q3	$5.49K	Buy	+29	New	+$6.3K	﹤0.01%	4263
2024 Q2	–	Sell	-4	Closed	-$739	–	5844
2024 Q1	$739	Hold	4	–	–	﹤0.01%	5393
2023 Q4	$1.54K	Hold	4	–	–	﹤0.01%	5364
2023 Q3	$1.93K	Hold	4	–	–	﹤0.01%	5238
2023 Q2	$4.13K	Hold	4	–	–	﹤0.01%	4981
2023 Q1	$4K	Sell	4 -3	-43%	-$3.64K	﹤0.01%	5077
2022 Q4	$8K	Buy	7 +2	+40%	+$2.44K	﹤0.01%	4408
2022 Q3	$6K	Sell	5 -1	-17%	-$1.79K	﹤0.01%	5023
2022 Q2	$11K	Buy	6 +2	+50%	+$4.89K	﹤0.01%	4376
2022 Q1	$18K	Buy	4 +1	+33%	+$3.91K	﹤0.01%	3630
2021 Q4	$21K	Buy	3 +1	+50%	+$7.18K	﹤0.01%	3606
2021 Q3	$8K	Buy	+2	New	+$9.71K	﹤0.01%	4542

Other funds holding ISPC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

GCP

Gill Capital Partners Denver, Colorado $348M AUM 14.74% 1-Year Est. Return

Tower Research Capital (TRC)'s ISPC Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its iSpecimen (ISPC) stake by 0.6% in Q1 2026, selling an estimated $11 and leaving 166 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #4732.

Tower Research Capital (TRC) first reported a position in ISPC in Q3 2021 and has held it in 18 quarters since. The position peaked at $21K in Q4 2021. 9 funds tracked by Wall St. Rank hold ISPC as of Q1 2026.

Tower Research Capital (TRC) held 166 shares of iSpecimen worth $1.04K as of Q1 2026.
Tower Research Capital (TRC) sold 1 iSpecimen share in Q1 2026, an estimated $11.
iSpecimen made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4732 holding.
Tower Research Capital (TRC) first reported a position in iSpecimen in Q3 2021 and has held it in 18 quarters since.
Tower Research Capital (TRC)'s iSpecimen position peaked at $21K in Q4 2021.
9 funds tracked by Wall St. Rank held iSpecimen as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.